Clinical Trial Search

Primary: Number of Patients Requiring Continuous Lorazepam Infusion — 2; 16 participants

Primary: Retention in Treatment — 28 Participants — p=0.0021

Primary: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 — 1.256772; 1.294178 Ratio of glutamate to creatine

Primary: Cumulative Lorazepam Dose Over the First Seven Days of Alcohol Withdrawal — 180.5; 112.5; 109.1 mg — p=0.64

Primary: Mean Length of Hospital Stay — 44.91; 50.50 hours

Primary: Benzodiazepine Doses Used to Treat Acutely-withdrawing Alcoholic Patients in the Baclofen-treated and Placebo-treated Groups — 14.1; 124.4 mg of benzodiazepine per 8 hours

Primary: Epworth Sleepiness Scale (ESS) — 6.35; 2.65 units on a scale

Primary: Treatment Adherence — 15 Participants

Primary: Negative Affect — 2.91; 2.47 units — p=.62

Primary: Percent Subjects Completely Abstinent — 44; 19; 33; 71 percent of participants — p=0.03

Primary: Total Lorazepam Dosage (in Milligrams) — 16.5; 3.4 milligrams of lorazepam

Primary: Drinking — 6; 8; 2 participants — p=<0.04

Primary: Craving to Drink — 31.1; 33.2 score on a scale — p=.065

Primary: Level of Intoxication (Subjective Response) on Each Condition Day After Drinking Relative to How They Felt When Arriving to the Lab on That Respective Day )Prior to…

Primary: Percent Days Drinking — 34.9; 31.9 percentage of days drinking — p=0.64

Primary: Withdrawal Symptoms Measured Using the Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) — 4.16; 6.57 score on a scale — p=0.067

Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants

Primary: Change in Blood Oxygen Level Dependent (BOLD) fMRI Signal for Alcohol Versus Non-alcohol Stimuli — 0.267390; 0.040281; 0.058670; -0.069048 BOLD response

Primary: Treatment Engagement — 36; 9 percentage of participants engaged

Primary: Weekly Percentage of Heaving Drinking Days — 37.6; 31.3 weekly percentage of heavy drinking days

Primary: Alcohol Craving Rating in Response to Saline Infusion — 1.704; 1.766 Units on a scale

Primary: Number of Drinks Felt Consumed at Baseline — 0; 0; 0; 0 drinks felt consumed

Primary: Percent of Heavy Drinking Days Per Week — 22.5; 53.9 percent of heavy drinking days

Primary: Breath Alcohol — 0.001; 0.075; 0.001; 0.071 gr/dL — p=0.28

Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — 198.3; 55.9 ng/mg

Primary: Craving to Drink — 36.5; 42.9 units on a scale — p=.003

Primary: Change From Baseline of Wakefulness After Sleep Onset (WASO) Measured by Polysomnography (PSG) — 100.88; 99.70; 103.51; 48.64 Minutes

Primary: Intervention Effects on Brain Functional Connectivity — 0.05; 0.19 percentage of Blood Oxygenation Level De

Primary: Visual Analogue Scale (VAS) of Craving Severity: 2 Arms — 2.38; 1.44 score on a scale

Primary: Craving to Drink — 33.84; 28.31 score on a scale — p=0.36